1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
TXBio Pilot Grant Program is sponsored by Texas Biologics (The University of Texas at Austin). A research initiative focused on the discovery, early development, clinical translation, production, and delivery of biologic therapies originating across The University of Texas at Austin. It aims to strengthen and expand biomedical translational research at UT Austin.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Pilot Grants | Texas Biologics Grants focused on the discovery, early development, clinical translation, production, and delivery of biologic therapies originating across The University of Texas at Austin. The 2027 TXBio Pilot Grant competition will open January 25, 2027.
TXBio Pilot Grant Program The Texas Biologics (TXBio) Pilot Grant Program is a research initiative, jointly led by the College of Natural Sciences and the Cockrell School of Engineering , focused on the discovery, early development, clinical translation, production, and delivery of biologic therapies originating across The University of Texas at Austin (UT Austin).
TXBio is supported by philanthropic gifts that are being deployed broadly to enhance the intellectual environment and infrastructure relevant to biologics research at UT Austin. A major goal of TXBio is to strengthen and expand biomedical translational research at UT Austin. One mechanism to achieve this goal is to provide financial support for projects in biologics discovery and development.
For the 2027 competition, TXBio will consider proposals that are broadly focused on: new biologic therapies with novel mechanisms of action, technology platforms to produce biologic therapies, and drug delivery technologies specific to the delivery of biologic therapies. Biologics include therapeutic proteins and peptides, nucleic acids, cell therapies and blood or tissue products.
The program seeks proposals aimed at generating “lead” therapeutics, delivery technologies, and production platforms, all focused on biologics. For the first two topics, performing proof-of-therapeutic-concept studies in vitro and in animal models, and addressing other issues critical to early drug development are of particular interest.
The use of AI or machine learning in project proposals is also of interest, for example, to optimize the design of a lead therapeutic candidate. Successful proposals should: For development of biologics: Lead to new molecular entities (composition of matter) that are clearly differentiated from other approaches targeting the same disease pathway or targeting novel disease pathways.
For development of delivery technologies for biologics: Lead to new compositions of matter and/or patentable process steps to address major problems such as tissue/cell selectivity, oral delivery (or delivery into the CSF), etc. of biologic drugs.
Successful submissions will need to clearly explain how the proposed approach/composition of matter is differentiated from the state of the art in the field and from the investigator’s on-going other research. For production platforms: Address what problem is being solved, how the approach addresses limitations in the state of the art and how it will enable important therapeutic modalities.
Include an experimental plan for validating the proposed mechanism of action, the effectiveness of delivery, or the efficiency of production. Outline possible barriers to clinical or commercial development (e.g., medical need, toxicities, manufacturing complexity) and how they may be overcome. Ultimately, the mission of TXBio is to make lasting contributions to human health and improve quality of life.
Therefore, projects should have a long-term view toward clinical trials and commercialization with an aim to bring biologic therapies and technologies developed at UT Austin to the patient. Applicants are encouraged to engage with UT Austin’s Discovery to Impact Life Science Technology Development (LSTD) Team to discuss their commercialization plans.
The LSTD Team can provide strategic guidance on intellectual property, licensing pathways, and technology development resources. To allow sufficient time for consultation and feedback email lifesciencetechdev@discoveries. utexas.
edu at least four weeks prior to proposal deadline. Download the 2026 TXBio Grant Competition Request for Proposals Congratulations, TXBio Pilot Grant Recipients! Awarded applications receive a research grant up to $150,000 to be used over a performance period of two years.
2026 Pilot Grant Awardees Development and Mechanistic Assessment of an IL-25/CTLA-4 bispecific antibody to improve the therapeutic index of anti-CTLA-4 therapy in immune checkpoint inhibition-responsive cancers Mark Badeaux, PhD, Cockrell School of Engineering Annalee Nguyen , Ph. D. , Cockrell School of Engineering An allergen delivery system for immunotherapy of food allergy Zhengrong Cui , Ph.
D. , College of Pharmacy Laura Suggs , PhD, Cockrell School of Engineering Robert O Williams III , PhD, College of Pharmacy Oral delivery of biological therapies through probiotic encoded circular RNADeveloping a stockpile-ready pan-filovirus vaccine Bryan Davies , PhD, College of Natural Sciences Andrew Ellington , Ph. D.
, College of Natural Sciences Developing a stockpile-ready panfilovirus vaccine Qian Yin , PhD, Cockrell School of Engineering Zhengrong Cui , Ph. D. , College of Pharmacy 2025 Pilot Grant Awardees Peptide and Chemotherapy Conjugate for Treating Pancreatic Cancer Eric Anslyn , Ph.
D. , College of Natural Sciences Kyaw Aung , Ph. D.
, Dell Medical School Stefano Tiziani , Ph. D. , College of Natural Sciences Alfredo Cardenas , Ph.
D. , College of Natural Sciences Development of Novel Lipid Nanoparticles Targeting Airway Basal Cells In Vivo for Long-term Genome Editing Debadyuti (Rana) Ghosh , Ph. D.
, College of Pharmacy AI-Driven Humanization of Uricase for Gout Therapy Edward Marcotte , Ph. D. , College of Natural Sciences Everett Stone , Ph.
D. , College of Natural Sciences Focused Ultrasound-Triggered Local Antibody Delivery for Pancreatic Cancer Huiliang (Evan) Wang , Ph. D.
, Cockrell School of Engineering Annalee Nguyen , Ph. D. , Cockrell School of Engineering William Matsui, M.
D. , Dell Medical School 2024 Pilot Grant Awardees Development of bifunctional peptide-antibiotic conjugates for the treatment of the pan-resistant pathogen Stenotrophomonas maltophilia Despoina Mavridou , Ph. D.
, College of Natural Sciences Kevin Dalby , Ph. D. , College of Pharmacy Jennifer Maynard , Ph.
D. , Cockrell School of Engineering Development and Mechanistic Studies of an Inosine-Degrading Enzyme for Breast Cancer Therapy Everett Stone , Ph. D.
, College of Natural Sciences Connexin-based biologics for restoration of synchronous beating following myocardial infarction Janeta Zoldan , Ph. D. , Cockrell School of Engineering Jeanne Stachowiak , Ph.
D. , Cockrell School of Engineering Zhengrong Cui , Ph. D.
, College of Pharmacy Smart EnteroPatho Nanoparticles for the Paracellular Delivery of Orally Administered Biologics Brian Belardi , Ph. D. , Cockrell School of Engineering Nicholas Peppas , Ph.
D. , Cockrell School of Engineering 2023 Pilot Grant Awardees Targeted in situ production of a HER2-specific nanobody for breast cancer Jaquelin Dudley , Ph. D.
, College of Natural Sciences Jennifer Maynard , Ph. D. , Cockrell School of Engineering Engineering RNA polymerases for efficiently producing mRNA vaccines Andrew Ellington , Ph.
D. , College of Natural Sciences 2022 Pilot Grant Awardees Engineered Proteoliposome Therapeutics for Glycocalyx Enhancement in Disease Aaron Baker , Ph. D.
, Cockrell School of Engineering Linda J. Noble-Haeusslein, Ph. D.
, Dell Medical School, College of Liberal Arts Eliminating Pancreatic Cancer Stem Cells with a Bispecific Antibody Binding a2b1 Integrin William Matsui, M. D. , Dell Medical School Jennifer Maynard , Ph.
D. , Cockrell School of Engineering Developing a Bifunctional Anti-biofilm Biologic Agent Walter L. Fast, Ph.
D. , College of Pharmacy Hugh D. Smyth , Ph.
D. , College of Pharmacy Developing Adaptable, Extracellular Drug Reservoirs for Treating Glioblastoma Benjamin Umlauf , Ph. D.
, Dell Medical School
According to the current listing, eligibility includes: Researchers and projects at The University of Texas at Austin focused on biologic therapies. Confirm the full requirements in the official notice before applying.
Applications for TXBio Pilot Grant Program are due January 25, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
TXBio Pilot Grant Program is funded by Texas Biologics (The University of Texas at Austin). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Texas. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The full ASPECT NOFO (DE-FOA-0003647) posted September 4, 2026, eleven days later than the Notice of Intent predicted. The real document splits $58 million across two topic areas with anticipated award counts of 0-7 and 0-3, a cost share that jumps from 20 percent to 50 percent mid-project, a mandatory five-page concept paper due October 9, and a university eligibility restriction that decides team structure before anyone writes a word.
Read articleThe Humana Foundation's first 2026 slate funded 13 nonprofits and five university research teams around senior and veteran emotional health, with awards from $150,000 to $3 million concentrated in Texas, Florida, and Kentucky. A second health equity slate is planned for fall 2026. Here is what the portfolio structure reveals about how this funder decides, and how aging-services and behavioral health organizations should position.
Read articleThe Hydrocarbons and Geothermal Energy Office's University Training and Research program funds coal, oil and gas, and geothermal R&D at U.S. colleges and universities — but every proposal must include a non-academic partner and must build training modules that outlive the award. The LOI deadline is October 1, 2026, with full applications 15 days later. Here is what that compressed window means and why the workforce framing changes what a competitive proposal looks like.
Read article